STRATFORD, N.J.--(BUSINESS WIRE)--Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced the appointment of Dr. Mert Sahin as Chief Executive Officer.
Dr. Sahin is a highly accomplished business executive with an impressive track record of success in the life sciences sector. He brings to Durin more than 20 years of experience in life sciences, pharmaceuticals, and medical devices, where he has demonstrated expertise in formulating and executing strategic go-to-market plans resulting in exceptional growth.
Dr. Sahin’s previous roles include executive positions at GE Healthcare, where he led marketing for its Imaging Business in the U.S. & Canada and was instrumental in growing the Molecular Imaging Business. He has held various commercial roles at Roche Diagnostics, Eurofins Genomics, Thermo Fisher Scientific and Dalan Animal Health. Dr. Sahin also co-founded Boston BioProcess, which helps alternative protein ingredient companies transition from the lab to commercial scale. He holds a PhD in Cell Biology from University of Hamburg, Germany.
Dr. Sahin will lead Durin Technologies as it commercializes its novel diagnostic tests for Alzheimer’s and Parkinson’s diseases, and develops its next generation of diagnostic tests for other diseases and disorders at their earliest stages.
Dr. Robert Nagele, Durin’s Founder and Chief Scientific Officer said, “Dr. Sahin’s team-centric, lead-by-example leadership style and innovative approach to fostering growth make him an excellent fit for Durin's aggressive growth plans. We're confident that his strategic vision, expertise, and determination will propel the company forward and allow Durin to seize the significant market opportunities available.”
“I am excited to join Durin, which will quickly become the innovation leader in neurodegenerative disease diagnostics,” said Dr. Sahin. “I look forward to working closely with the team to advance Durin to the next stage of its commercial success.”
About Durin Technologies, Inc.
Durin Technologies develops non-invasive, easy access diagnostic tests for the most prevalent and devastating neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. Its rapid-result, high-accuracy DuritectTM diagnostic tests make early detection and monitoring of disease progression possible – in a decade or more prior to symptoms in some cases. Durin’s first two tests – for Alzheimer's and Parkinson’s – will come to market in 2024, followed by tests for other diseases. The company’s groundbreaking science creates a scalable platform for diagnostic tests that will extend beyond the multi-billion-dollar neurodegenerative diagnostics market into the much larger, broader disease diagnostic market.
Learn more: durintechnologies.com
